Oxford BioDynamics Plc

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: GB00BD5H8572
GBP
0.00
0 (-32.5%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

Weak Long Term Fundamental Strength with an average Return on Equity (ROE) of 0%

  • Poor long term growth as Net Sales has grown by an annual rate of 10.40% and Operating profit at -170.79% over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -9.69
2

The company has declared Negative results for the last 3 consecutive quarters

3

Risky -

4

Consistent Underperformance against the benchmark over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

GBP 12 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.09

stock-summary
Return on Equity

-971.06%

stock-summary
Price to Book

10.77

Revenue and Profits:
Net Sales:
(Quarterly Results - )
Net Profit:
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-46.0%
0%
-46.0%
6 Months
-78.4%
0%
-78.4%
1 Year
-96.52%
0%
-96.52%
2 Years
-97.87%
0%
-97.87%
3 Years
-98.52%
0%
-98.52%
4 Years
-99.54%
0%
-99.54%
5 Years
-99.62%
0%
-99.62%

Oxford BioDynamics Plc for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
10.40%
EBIT Growth (5y)
-170.79%
EBIT to Interest (avg)
-9.69
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.58
Sales to Capital Employed (avg)
0.12
Tax Ratio
2.93%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0

Valuation key factors

Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.75
EV to EBIT
-0.58
EV to EBITDA
-0.66
EV to Capital Employed
2.77
EV to Sales
6.97
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-475.74%
ROE (Latest)
-199.98%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bullish
RSI
Bullish
Bollinger Bands
Mildly Bearish
Sideways
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "alert": "No Quarterly Results declared by Oxford BioDynamics Plc"
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Sep'23",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Sep 2023 is 150.00% vs -33.33% in Sep 2022",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Sep 2023 is -61.19% vs 0.00% in Sep 2022",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Sep'22",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.50",
          "val2": "0.20",
          "chgp": "150.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-9.60",
          "val2": "-7.90",
          "chgp": "-21.52%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.20",
          "val2": "1.10",
          "chgp": "-209.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-10.80",
          "val2": "-6.70",
          "chgp": "-61.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-21,558.80%",
          "val2": "-58,928.60%",
          "chgp": "3,736.98%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Annual Results Snapshot (Consolidated) - Sep'23stock-summary

Sep'23
Sep'22
Change(%)
Net Sales
0.50
0.20
150.00%
Operating Profit (PBDIT) excl Other Income
-9.60
-7.90
-21.52%
Interest
0.20
0.20
Exceptional Items
-1.20
1.10
-209.09%
Consolidate Net Profit
-10.80
-6.70
-61.19%
Operating Profit Margin (Excl OI)
-21,558.80%
-58,928.60%
3,736.98%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Sep 2023 is 150.00% vs -33.33% in Sep 2022

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Sep 2023 is -61.19% vs 0.00% in Sep 2022

stock-summaryCompany CV
About Oxford BioDynamics Plc stock-summary
stock-summary
Oxford BioDynamics Plc
Pharmaceuticals & Biotechnology
Oxford BioDynamics Plc is a biotechnology company, which is engaged in biomarker research and development. The Company focuses on the discovery and development of biomarkers for use within the pharmaceutical and biotechnology industry. Its geographical segments include UK and Malaysia. Its EpiSwitch is an industrial platform for the discovery, evaluation, validation and monitoring of a class of epigenetic biomarkers known as chromosome conformation signatures (CCSs). EpiSwitch is a biomarker technology platform that facilitates pharmaceutical and biotechnology companies in their therapeutic development programs and the development of companion diagnostics. The EpiSwitch technology has validated biomarkers in a range of diseases, including Alzheimer's disease, breast cancer, ulcerative colitis and liver cancer. Its service offering includes predictive biomarkers, prognostic biomarkers, residual disease monitoring biomarkers, diagnostic biomarkers and companion diagnostic biomarkers.
Company Coordinates stock-summary
Company Details
26 Beaumont Street , OXFORD None : OX1 2NP
Registrar Details